Evaluation of transarterial chemoembolization combined with percutaneous ethanol ablation for large hepatocellular carcinoma

Table 3 Factors affecting survival by univariate analysis n (%)

Variables	Class	Survival			P value
		1 yr	3 yr	5 yr
Sex	A	27 (51.9)	16 (30.8)	9 (17.3)
	B	7 (63.6)	4 (36.4)	2 (18.2)	0.9241
Age (yr)	A	21 (58.3)	11 (30.6)	5 (13.9)
	B	13 (48.1)	9 (33.3)	6 (22.2)	0.2231
No. of lesions	A	25 (58.1)	17 (39.5)	10 (23.3)
	B	9 (45.0)	3 (15.0)	1 (5.0)	0.01451
Tumor size	A	28 (68.3)	18 (43.9)	11 (26.8)
	B	6 (27.3)	2 (9.1)	0 (0)	0.00411
Tumor extension	A	29 (63.0)	18 (39.1)	11 (23.9)
	B	5 (29.4)	2 (11.8)	0 (0)	0.00541
Tumor margin	A	25 (89.3)	15 (53.6)	11 (39.3)
	B	9 (25.7)	5 (14.3)	0 (0)	0.00521
AFP	A	16 (72.7)	10 (45.5)	9 (40.9)
	B	18 (43.9)	10 (24.4)	2 (4.9)	0.00301
Portal thrombosis	A	31 (60.8)	18 (35.3)	11 (21.6)
	B	3 (25.0)	2 (16.7)	0 (0)	0.01111
Ascites	A	32 (57.1)	19 (33.9)	11 (19.6)
	B	2 (28.6)	1 (14.3)	0 (0)	0.01151
Child grade	A	28 (73.7)	17 (44.7)	11 (28.9)
	B	6 (24.0)	3 (12.0)	0 (0)	0.01321
Okuda stage	A	22 (75.9)	14 (48.3)	10 (34.5)
	B	12 (35.3)	6 (17.6)	1 (2.9)	0.01501
TACE (No. of times)	A	3 (27.2)	2 (18.2)	1 (9.1)
	B	13 (50.0)	7 (26.9)	3 (11.5)
	C	13 (65.0)	8 (40.0)	5 (25.0)
	D	5 (83.3)	3 (50.0)	2 (33.3)	0.17192
PEA (No. of times)	A	1 (33.3)	0 (0)	0 (0)
	B	2 (33.3)	1 (16.7)	0 (0)
	C	16 (48.5)	10 (32.3)	5 (16.1)
	D	15 (65.2)	9 (39.1)	6 (26.1)	< 0.00012
Total ethanol dose	A	0 (0)	0 (0)	0 (0)
	B	2 (33.3)	1 (16.7)	0 (0)
	C	15 (51.7)	9 (31.0)	5 (16.1)
	D	17 (73.9)	10 (43.5)	6 (26.1)	< 0.00012

¹P value: B vs A;

²P value: D vs A. AFP: α-fetoprotein; TACE: Transcatheter arterial chemoembolization; PEA: Percutaneous ethanol ablation.